Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/34
Title: Treatment outcomes for serious infections caused by methicillin-resistant staphylococcus aureus with reduced vancomycin susceptibility.
Authors: Howden, Benjamin P.
Ward, Peter B.
Charles, Patrick G. P.
Korman, Tony M.
Fuller, Andrew
du Cros, Philipp
Grabsch, Elizabeth A.
Roberts, Sally A.
Robson, Jenny
Read, Kerry
Bak, Narin
Hurley, James C.
Johnson, Paul D. R.
Morris, Arthur J.
Mayall, Barrie C.
Grayson, M. Lindsay
Issue Date: 2004
Publisher: University of Chicago Press
Place of publication: Chicago
Publication Title: Clinical Infectious Diseases
Volume: 38
Issue: 4
Start Page: 521
End Page: 528
Abstract: Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS.
URI: http://hdl.handle.net/11054/34
Resource Link: http://cid.oxfordjournals.org/content/38/4/521.long
ISSN: 1058-4838
Internal ID Number: 00021
Health Subject: ACETAMIDES - THERAPEUTIC USE
ANTI INFECTIVE AGENTS - THERAPEUTIC USE
METHICILLIN RESISTANCE
MICROBIAL SENSITIVITY TESTS
OXAXOLIDNONES - THERAPEUTIC USE
RIFAMPIN - THERAPEUTIC USE
STAPHYLOCOCCAL INFECTIONS - DRUG THERAPY
STAPHYLOCOCCUS AUREUS - DRUG EFFECTS
VANCOMYCIN
VANCOMYCIN RESISTANCE
ACETAMIDES
ANTI-INFECTIVE AGENTS
OXAZOLIDINONES
RIFAMPIN
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.